vs
Side-by-side financial comparison of Astera Labs, Inc. (ALAB) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $270.6M, roughly 1.3× Astera Labs, Inc.). Astera Labs, Inc. runs the higher net margin — 16.6% vs 13.2%, a 3.4% gap on every dollar of revenue. On growth, Astera Labs, Inc. posted the faster year-over-year revenue change (91.8% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $76.6M). Over the past eight quarters, Astera Labs, Inc.'s revenue compounded faster (103.6% CAGR vs 0.4%).
Astera Labs, Inc. is an American fabless semiconductor manufacturer and artificial intelligence company. The company specializes in designing high-speed connectivity solutions for data centers and AI infrastructure. The company has been listed on the Nasdaq since March 2024.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
ALAB vs HAE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $270.6M | $339.0M |
| Net Profit | $45.0M | $44.7M |
| Gross Margin | 75.6% | 59.7% |
| Operating Margin | 24.7% | 19.9% |
| Net Margin | 16.6% | 13.2% |
| Revenue YoY | 91.8% | -2.7% |
| Net Profit YoY | 82.0% | 19.3% |
| EPS (diluted) | $0.25 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $270.6M | $339.0M | ||
| Q3 25 | $230.6M | $327.3M | ||
| Q2 25 | $191.9M | $321.4M | ||
| Q1 25 | $159.4M | $330.6M | ||
| Q4 24 | $141.1M | $348.5M | ||
| Q3 24 | $113.1M | $345.5M | ||
| Q2 24 | $76.8M | $336.2M | ||
| Q1 24 | $65.3M | — |
| Q4 25 | $45.0M | $44.7M | ||
| Q3 25 | $91.1M | $38.7M | ||
| Q2 25 | $51.2M | $34.0M | ||
| Q1 25 | $31.8M | $58.0M | ||
| Q4 24 | $24.7M | $37.5M | ||
| Q3 24 | $-7.6M | $33.8M | ||
| Q2 24 | $-7.5M | $38.4M | ||
| Q1 24 | $-93.0M | — |
| Q4 25 | 75.6% | 59.7% | ||
| Q3 25 | 76.2% | 59.5% | ||
| Q2 25 | 75.8% | 59.8% | ||
| Q1 25 | 74.9% | 58.4% | ||
| Q4 24 | 74.0% | 55.5% | ||
| Q3 24 | 77.7% | 54.2% | ||
| Q2 24 | 77.9% | 52.0% | ||
| Q1 24 | 77.4% | — |
| Q4 25 | 24.7% | 19.9% | ||
| Q3 25 | 24.0% | 17.9% | ||
| Q2 25 | 20.7% | 16.8% | ||
| Q1 25 | 7.1% | 21.6% | ||
| Q4 24 | 0.1% | 16.9% | ||
| Q3 24 | -7.9% | 15.0% | ||
| Q2 24 | -31.7% | 11.8% | ||
| Q1 24 | -127.1% | — |
| Q4 25 | 16.6% | 13.2% | ||
| Q3 25 | 39.5% | 11.8% | ||
| Q2 25 | 26.7% | 10.6% | ||
| Q1 25 | 20.0% | 17.5% | ||
| Q4 24 | 17.5% | 10.8% | ||
| Q3 24 | -6.7% | 9.8% | ||
| Q2 24 | -9.8% | 11.4% | ||
| Q1 24 | -142.5% | — |
| Q4 25 | $0.25 | $0.95 | ||
| Q3 25 | $0.50 | $0.81 | ||
| Q2 25 | $0.29 | $0.70 | ||
| Q1 25 | $0.18 | $1.17 | ||
| Q4 24 | $1.23 | $0.74 | ||
| Q3 24 | $-0.05 | $0.66 | ||
| Q2 24 | $-0.05 | $0.74 | ||
| Q1 24 | $-1.77 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.6M | $363.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $1.4B | $911.5M |
| Total Assets | $1.5B | $2.5B |
| Debt / EquityLower = less leverage | — | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.6M | $363.4M | ||
| Q3 25 | $140.4M | $296.4M | ||
| Q2 25 | $162.3M | $292.9M | ||
| Q1 25 | $86.4M | $306.8M | ||
| Q4 24 | $79.6M | $320.8M | ||
| Q3 24 | $126.1M | $299.3M | ||
| Q2 24 | $421.1M | $344.4M | ||
| Q1 24 | $696.1M | — |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.4B | $911.5M | ||
| Q3 25 | $1.3B | $849.2M | ||
| Q2 25 | $1.1B | $882.3M | ||
| Q1 25 | $1.0B | $820.8M | ||
| Q4 24 | $964.8M | $906.9M | ||
| Q3 24 | $889.6M | $878.9M | ||
| Q2 24 | $845.3M | $905.4M | ||
| Q1 24 | $808.8M | — |
| Q4 25 | $1.5B | $2.5B | ||
| Q3 25 | $1.4B | $2.4B | ||
| Q2 25 | $1.3B | $2.5B | ||
| Q1 25 | $1.1B | $2.5B | ||
| Q4 24 | $1.1B | $2.5B | ||
| Q3 24 | $983.1M | $2.5B | ||
| Q2 24 | $915.5M | $2.5B | ||
| Q1 24 | $864.9M | — |
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $95.3M | $93.6M |
| Free Cash FlowOCF − Capex | $76.6M | $87.2M |
| FCF MarginFCF / Revenue | 28.3% | 25.7% |
| Capex IntensityCapex / Revenue | 6.9% | 1.9% |
| Cash ConversionOCF / Net Profit | 2.12× | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | $281.8M | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $95.3M | $93.6M | ||
| Q3 25 | $78.2M | $111.3M | ||
| Q2 25 | $135.4M | $17.4M | ||
| Q1 25 | $10.5M | $116.6M | ||
| Q4 24 | $39.7M | $43.8M | ||
| Q3 24 | $63.5M | $48.8M | ||
| Q2 24 | $29.8M | $-27.4M | ||
| Q1 24 | $3.7M | — |
| Q4 25 | $76.6M | $87.2M | ||
| Q3 25 | $65.9M | $106.3M | ||
| Q2 25 | $133.3M | $13.6M | ||
| Q1 25 | $6.0M | $100.9M | ||
| Q4 24 | $24.3M | $35.2M | ||
| Q3 24 | $46.8M | $39.4M | ||
| Q2 24 | $28.5M | $-33.1M | ||
| Q1 24 | $228.0K | — |
| Q4 25 | 28.3% | 25.7% | ||
| Q3 25 | 28.6% | 32.5% | ||
| Q2 25 | 69.5% | 4.2% | ||
| Q1 25 | 3.7% | 30.5% | ||
| Q4 24 | 17.2% | 10.1% | ||
| Q3 24 | 41.4% | 11.4% | ||
| Q2 24 | 37.1% | -9.8% | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 6.9% | 1.9% | ||
| Q3 25 | 5.3% | 1.5% | ||
| Q2 25 | 1.1% | 1.2% | ||
| Q1 25 | 2.8% | 4.7% | ||
| Q4 24 | 10.9% | 2.5% | ||
| Q3 24 | 14.8% | 2.7% | ||
| Q2 24 | 1.7% | 1.7% | ||
| Q1 24 | 5.2% | — |
| Q4 25 | 2.12× | 2.09× | ||
| Q3 25 | 0.86× | 2.88× | ||
| Q2 25 | 2.64× | 0.51× | ||
| Q1 25 | 0.33× | 2.01× | ||
| Q4 24 | 1.61× | 1.17× | ||
| Q3 24 | — | 1.44× | ||
| Q2 24 | — | -0.71× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALAB
Segment breakdown not available.
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
